The trajectory of the erectile dysfunction drug presents a challenging picture for shareholders. While the initial launch generated massive returns, the end of its intellectual property protection opened the avenue to https://top10bookmark.com/story21491416/sildenafil-and-the-pharmaceutical-industry-a-risky-investment